Skip to main content

Table 1 Efficacy of drotrecogin alpha activated as a function of baseline severity of illness in phase III trials

From: The staging of sepsis: understanding heterogeneity in treatment efficacy

 

28 Day mortality (%)

   

APACHE II score

Placebo

rhAPC

Odds ratio

95% CI

p

≤24

   PROWESS

19.1

18.7

   

   ADDRESS

16.0

16.9

   

   Pooled

16.8

17.4

1.04

0.86–1.26

0.72

>24

   PROWESS

43.1

31.5

   

   ADDRESS

24.8

29.4

   

   Pooled

38.0

30.9

0.73

0.57–0.94

0.01

Overall mortality

22.4

21.0

0.92

0.79–1.06

0.26

  1. APACHE, Acute Physiology, Age, and Chronic Health Evaluation; CI, confidence interval; rhAPC, recombinant human activated protein C.
Back to article page

Critical Care

ISSN: 1364-8535